TrialDiabetes, obesity & metabolism2021

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.

Linong Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.